×
Mannatech Receivables 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Mannatech receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
View More
Mannatech Receivables 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Mannatech receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$71.1B
Zoetis (ZTS)
$68.9B
Takeda Pharmaceutical (TAK)
$47.3B
Daiichi Sankyo, - (DSNKY)
$46B
BeOne Medicines - (ONC)
$32.9B
Sandoz Group AG (SDZNY)
$27.7B
Summit Therapeutics (SMMT)
$18.4B
Merck (MKKGY)
$16.3B
Shionogi (SGIOY)
$14.7B
United Therapeutics (UTHR)
$13.8B
Neurocrine Biosciences (NBIX)
$13.7B
Orion OYJ (ORINY)
$11.2B
IPSEN (IPSEY)
$11.2B
Madrigal Pharmaceuticals (MDGL)
$9.4B
Eisai (ESAIY)
$9.1B
Corcept Therapeutics (CORT)
$7.3B
Ionis Pharmaceuticals (IONS)
$6.8B
Stevanato Group S.p.A (STVN)
$6.8B
Grifols, S.A (GRFS)
$6.7B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.9B
Hypermarcas (HYPMY)
$2.8B
Procaps Group, S.A (PROCF)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$2.1B